CMV再激活对AML异基因造血干细胞移植后复发的影响取决于疾病阶段和ATG
该回顾性研究分析687例接受基于环孢素免疫抑制的AML异基因HCT患者,探讨CMV再激活对移植结局的影响如何随AML疾病阶段和体内ATG T细胞清除而变化。无ATG时CMV再激活与复发显著降低相关,且晚期疾病比CR1更明显;ATG暴露在晚期疾病中消除此保护作用,在CR1中反而增加复发。CMV再激活在无ATG的CR1患者中与非复发死亡率显著增加相关。
要点
- 无ATG时CMV再激活与AML复发显著降低相关,晚期疾病比CR1更明显。
- ATG暴露在晚期疾病中消除CMV再激活的复发保护,在CR1中反转为复发增加。
- CMV再激活在无ATG的CR1患者中与非复发死亡率显著增加相关。
核心结论
- ATG和疾病阶段以相反方向调节HCT后CMV再激活对AML复发的影响,提示抗病毒与抗肿瘤免疫交互的复杂性。
研究设计与样本
- 回顾性分析687例接受基于环孢素免疫抑制的异基因HCT的AML患者,按疾病阶段和体内ATG T细胞清除分层。
主要发现
- CMV再激活后仅晚期疾病患者的无事件生存率显著高于无CMV者。
临床怎么用
- 评估HCT后CMV再激活对复发风险的影响时,需结合AML疾病阶段和是否使用ATG分层解读。
局限性
- 回顾性设计;原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cytomegalovirus (CMV) reactivation is a frequent complication after allogeneic hematopoietic cell transplantation (HCT), whose impact on clinical outcome, in particular on leukemic relapse, is controversial. We retrospectively analyzed 687 HCT recipients with acute myeloid leukemia (AML) and ciclosporin-based immunosuppression to better understand the differential impact of CMV on transplant outcomes depending on AML disease stage and in vivo T cell depletion with antithymocyte globulin (ATG). Without ATG, CMV reactivation associated with significantly reduced relapse, yet its effect was more pronounced for advanced disease AML (P = .0002) than for patients in first complete remission (CR1, P = .0169). Depending on the disease stage, ATG exposure abrogated relapse protection following CMV reactivation in advanced stages (P = .796), while it inverted its effect into increased relapse for CR1 patients (P = .0428). CMV reactivation was associated with significantly increased nonrelapse mortality in CR1 patients without ATG (P = .0187) but not in those with advanced disease and ATG. Following CMV reactivation, only patients with advanced disease had significantly higher event-free survival rates as compared with patients without CMV. Overall, our data suggest that both ATG and disease stage modulate the impact of post-HCT CMV reactivation in opposite directions, revealing a level of complexity that warrants future studies regarding the interplay between antivirus and antitumor immunity.
引用
- Turki AT, Tsachakis-Mück N, Leserer S, et al. Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG. Blood Adv. 2022. PMID: 34619756. doi:10.1182/bloodadvances.2021005509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。